List of Excipients in Branded Drug BIJUVA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Mayne Pharma LLC	BIJUVA	estradiol and progesterone	50261-211	ALCOHOL	2032-11-21
Mayne Pharma LLC	BIJUVA	estradiol and progesterone	50261-211	AMMONIA	2032-11-21
Mayne Pharma LLC	BIJUVA	estradiol and progesterone	50261-211	ETHYL ACETATE	2032-11-21

Bijuva Excipient Strategy and Commercial Opportunities

Last updated: August 8, 2026

Bijuva is an oral, fixed-dose softgel capsule containing estradiol and progesterone for moderate-to-severe vasomotor symptoms associated with menopause in women with a uterus. Its excipient profile creates opportunities in allergy risk reduction, capsule-shell innovation, bioavailability, manufacturing efficiency, and differentiated generic or follow-on products. The principal commercial constraint is that excipient changes can alter dissolution, absorption, stability, and labeling requirements for an FDA-approved combination product.

What is Bijuva and how is it formulated?

Bijuva contains 1 mg of estradiol and 100 mg of progesterone in a single oral capsule. The product is taken once daily in the evening with food. It was approved by the FDA in October 2018 under NDA 210852. The approved indication is treatment of moderate-to-severe vasomotor symptoms due to menopause in women with an intact uterus. [1]

The labeled inactive ingredients include:

Formulation element	Bijuva role	Commercial relevance
Peanut oil	Lipid vehicle for estradiol and progesterone	Allergen concern; potential reformulation target
Gelatin	Softgel shell	Animal-origin and religious or dietary restrictions
Glycerin	Plasticizer and humectant	Shell flexibility and stability
Sorbitol	Plasticizer or shell-processing aid	Moisture sensitivity and shell performance
Titanium dioxide	Opacifier	Regulatory and market-access scrutiny
Colorants	Capsule identification	Potential simplification for generic products

The exact inactive-ingredient listing and colorant composition should be controlled against the current FDA-approved prescribing information and product labeling. [1,2]

Why does Bijuva require a lipid-based excipient system?

Estradiol and progesterone are poorly water-soluble steroid hormones. Progesterone has particularly low aqueous solubility and high dependence on formulation and food conditions. A lipid vehicle can improve wetting, dispersion, and gastrointestinal absorption.

Bijuva’s food instruction is commercially important. Administration with food affects progesterone and estradiol exposure, which means an excipient change that improves self-emulsification or reduces food dependence could support a differentiated product claim if demonstrated in appropriate pharmacokinetic studies.

What excipients create the largest commercial opportunities for Bijuva?

The most attractive opportunities involve replacing peanut oil, improving lipid dispersion, and developing a non-gelatin capsule shell.

Peanut-oil replacement

Peanut oil is the clearest strategic weakness in the current formulation. It can create:

• Allergy-related prescribing and dispensing concerns
• Hospital and institutional formulary restrictions
• Patient reluctance
• Labeling complexity
• Product-liability and supply-chain exposure
• Restrictions in markets with heightened allergen controls

Potential replacement vehicles include medium-chain triglycerides, hydrogenated vegetable oils, soybean-derived oils, sesame oil alternatives, oleic-rich oils, and synthetic lipid excipients. Each option would require evaluation of hormone solubility, oxidation, peroxide formation, capsule compatibility, dissolution, and bioavailability.

A peanut-oil-free Bijuva formulation could support a commercially meaningful product position if it preserves exposure while reducing allergy-related restrictions. The strongest opportunity is a direct replacement that maintains the existing dose and administration schedule, because that may limit clinical-development complexity.

Self-emulsifying drug-delivery systems

A self-emulsifying drug-delivery system could improve dispersion of estradiol and progesterone after oral administration. Candidate systems may combine:

• A lipid phase
• A surfactant
• A co-surfactant or co-solvent
• A capsule-compatible antioxidant
• A precipitation inhibitor

The system should be designed to avoid excessive surfactant loading. High surfactant concentrations may affect gastrointestinal tolerability, shell integrity, or long-term stability.

The commercial objective would be to reduce fed-state dependence, improve exposure consistency, or reduce interpatient variability. These claims require comparative pharmacokinetic data against the approved product.

Non-gelatin capsule shells

A vegetarian or non-animal softgel shell could expand access in markets where gelatin is commercially unattractive. Potential materials include modified starch, pullulan, hydroxypropyl starch, carrageenan-based systems, and other polysaccharide combinations.

The technical barriers are substantial. A non-gelatin shell must match gelatin in:

• Oxygen and moisture protection
• Mechanical strength
• Sealing performance
• Fill compatibility
• Dissolution
• Long-term stability
• Manufacturing speed
• Printing and visual identification

A shell change could support a premium or specialty-market product, but it would likely require more than a simple inactive-ingredient substitution if dissolution or release characteristics change.

Antioxidant systems

Estradiol and progesterone can be exposed to oxidative degradation during manufacturing and storage. Lipid vehicles also create oxidation risk. Antioxidant options may include tocopherols, ascorbyl palmitate, propyl gallate, or other lipid-compatible antioxidants.

An antioxidant strategy should be selected based on degradation pathways rather than general excipient preference. The relevant tests include peroxide value, acid value, degradant formation, capsule-shell interaction, and accelerated stability.

How does Bijuva compare with other menopausal hormone-therapy products?

Bijuva’s primary differentiation is the combination of estradiol and progesterone in one oral capsule. Competing products include separate oral estradiol and micronized progesterone products, transdermal estradiol combined with oral progesterone, and other fixed-dose hormone combinations.

Product approach	Main advantage	Excipient opportunity	Commercial limitation
Bijuva oral combination	One capsule and fixed dosing	Peanut-oil replacement, food-effect reduction	Oral systemic exposure and food instruction
Separate estradiol plus progesterone	Flexible dose adjustment	Patient-specific formulation selection	Two products and lower convenience
Transdermal estradiol plus oral progesterone	Reduced first-pass estradiol exposure	Adhesive, patch, or gel technology	More complex administration
Vaginal estrogen products	Local therapy	Mucoadhesive and low-dose delivery systems	Different therapeutic objective
Compounded hormone products	Custom dosing	Customized vehicles	Variable quality and non-FDA-approved status

Bijuva’s strongest formulation advantage is convenience. Its most important formulation weakness is the combination of a lipid-sensitive oral product, food-related administration requirements, peanut oil, and an animal-derived softgel shell.

What formulations are protected by Bijuva-related intellectual property?

Bijuva’s commercial protection is likely to involve a combination of product, formulation, method-of-use, and regulatory exclusivity rights. The relevant rights may cover:

• The estradiol-progesterone combination
• Specific dose ratios
• Oral softgel delivery
• Lipid vehicles
• Treatment of vasomotor symptoms
• Use in postmenopausal women with a uterus
• Manufacturing or capsule-filling processes

Excipient innovation can create a separate patent position if it produces a technically defined formulation rather than merely substituting one pharmaceutically acceptable excipient for another.

Potentially protectable subject matter includes:

1. A peanut-oil-free lipid composition with specified estradiol and progesterone solubility.
2. A self-emulsifying formulation with defined droplet size or dispersion performance.
3. A capsule shell that limits oxidation or improves moisture protection.
4. A formulation that reduces food-effect variability.
5. A manufacturing process that improves content uniformity or reduces degradation.
6. A stability profile that enables longer shelf life or broader storage conditions.

A generic manufacturer should distinguish between an excipient substitution that can be supported through an ANDA and an improved formulation that requires separate clinical or pharmacokinetic development.

When did Bijuva lose FDA regulatory exclusivity?

Bijuva was approved on October 10, 2018. Because the active ingredients were previously known, the product is generally analyzed as a new combination rather than a new chemical entity. The relevant FDA exclusivity framework is therefore more likely to involve three-year exclusivity for new clinical investigations supporting approval rather than five-year new-chemical-entity exclusivity. [1,3]

The three-year period would have expired in October 2021, subject to the precise scope of the FDA-granted exclusivity and any applicable regulatory events. Expiration of regulatory exclusivity does not eliminate patent protection.

Milestone	Date or status
FDA approval	October 10, 2018
Likely three-year clinical-investigation exclusivity period	Through approximately October 2021
Orange Book patent status	Must be evaluated against the current FDA Orange Book
Generic-entry timing	Dependent on applicable patents, ANDA review, and litigation
Biosimilar pathway	Not applicable; Bijuva is a small-molecule drug

What is the Orange Book status of Bijuva?

Bijuva is a small-molecule drug listed under an FDA-approved NDA, so the relevant competitive pathway is an ANDA, not a biosimilar application. Orange Book analysis should cover:

• Listed patents
• Patent use codes
• Patent expiration dates
• Pediatric exclusivity
• Paragraph IV certifications
• Patent litigation under the Hatch-Waxman framework
• Whether a generic can omit a protected indication under a section viii statement

The commercial significance of the Orange Book record is direct. A generic manufacturer may be able to copy the active ingredients, strength, dosage form, and route while using different inactive ingredients, subject to pharmaceutical-equivalence and bioequivalence requirements.

No biosimilar risk exists because estradiol and progesterone are chemically synthesized small molecules, not biologics.

Which companies are challenging Bijuva with generic products?

The generic competitive field is expected to include manufacturers capable of producing oral estradiol-progesterone softgels. Competitive entry depends on FDA-approved ANDAs and any associated paragraph IV litigation. The principal manufacturing capabilities required are:

• Hormone micronization and handling
• Low-dose content uniformity
• Softgel encapsulation
• Lipid-fill compatibility
• Potency and degradant control
• Specialized containment for potent hormonal ingredients
• Bioequivalence testing under fed and fasting conditions where required

A generic company may pursue a formulation that avoids peanut oil or uses a different shell system. That approach can reduce dependence on the reference formulation but may increase development risk if excipient differences affect absorption.

A public statement that a specific manufacturer has filed a paragraph IV certification, entered litigation, or obtained FDA approval should be based on the current FDA Orange Book, FDA product approvals, and court docket records. Patent conclusions should not be inferred from the existence of a generic listing alone.

What generic launch risks exist for Bijuva?

The most plausible launch scenarios are:

At-risk launch after paragraph IV certification

A generic manufacturer may launch before patent expiration after asserting that listed patents are invalid, unenforceable, or not infringed. The reference sponsor could seek a 30-month stay under the Hatch-Waxman Act if statutory requirements are met. [4]

Authorized generic or settlement-based entry

A settlement may establish a future entry date, supply arrangement, or license. The economic impact depends on whether one or several manufacturers receive entry rights and whether the agreement includes restrictions on formulation or market channels.

Formulation-different generic entry

A generic applicant may use a different oil, shell, colorant, or antioxidant while maintaining pharmaceutical equivalence. This is the most relevant pathway for excipient competition.

Delayed entry caused by manufacturing complexity

Softgel production can delay launch even after regulatory approval. Low-dose hormone products require tight process control. A manufacturer may also face scale-up, capsule leakage, fill-weight, dissolution, or stability failures.

How strong is the Bijuva patent estate?

Patent strength depends on claim scope, remaining term, prosecution history, validity risk, and the number of non-infringing formulation routes. A broad claim covering the estradiol-progesterone combination would present a larger barrier than a narrow claim limited to a specific oil, shell, ratio, or manufacturing step.

The estate is commercially stronger if it covers several independent features:

• Active-ingredient combination
• Dose ratio
• Softgel dosage form
• Lipid vehicle
• Food-effect control
• Manufacturing process
• Method of treating vasomotor symptoms

It is weaker if protection depends primarily on a narrow excipient combination that a generic manufacturer can replace without changing bioequivalence. Excipient patents are most defensible when they connect the composition to a measurable technical result, such as improved stability, reduced food dependence, enhanced dissolution, or lower variability.

What licensing deals could support Bijuva expansion?

Licensing opportunities fall into four categories.

Excipient technology licensing

A lipid-delivery or self-emulsifying-system owner could license technology to the product sponsor or a generic manufacturer. The deal could include milestone payments, royalties, or field-of-use restrictions.

Softgel manufacturing partnerships

A contract development and manufacturing organization with hormone-containment capability could provide manufacturing capacity. The value of the partnership would increase if the manufacturer has validated non-gelatin softgel technology or multi-site supply redundancy.

Geographic licensing

Bijuva’s formulation could be licensed outside the United States to companies with established menopause portfolios. Geographic expansion may require local registration, different allergen labeling, and country-specific excipient acceptability.

Generic development partnerships

A formulation developer could partner with a generic manufacturer to create a peanut-oil-free version, a vegetarian-shell product, or a lower-food-effect formulation. The key commercial issue is whether the resulting product remains an ANDA candidate or becomes a separate 505(b)(2) product with differentiated claims.

What FDA regulatory pathway applies to an improved Bijuva formulation?

The pathway depends on the level of change.

Product change	Likely regulatory analysis
Different colorant with unchanged performance	ANDA or post-approval supplement, depending on sponsor and product
Different oil with demonstrated bioequivalence	Potential ANDA strategy for a generic
New shell material affecting release	More extensive pharmaceutical and bioequivalence work
Reduced food effect	Likely requires comparative clinical pharmacokinetic evidence
New dose or indication	Supplemental NDA or separate development program
New delivery technology	Potential 505(b)(2) pathway
New route of administration	New regulatory program

For the reference sponsor, a meaningful excipient reformulation would likely require an NDA supplement, supported by chemistry, manufacturing, and controls data, stability, dissolution, and potentially clinical pharmacology. For a new sponsor, a 505(b)(2) application may be more suitable if the product relies on published data or the approved Bijuva product while introducing a meaningful formulation difference. [5]

How large is the commercial opportunity?

The commercial opportunity is concentrated in three segments:

1. A peanut-oil-free oral combination for patients and prescribers concerned about allergen exposure.
2. A vegetarian or animal-origin-free softgel for specialty pharmacies and international markets.
3. A formulation with lower food-effect variability and more predictable exposure.

The highest-probability commercial product is a direct, peanut-oil-free substitution with the same strengths and capsule format. It addresses a clear labeling and prescribing issue without requiring a completely new delivery platform.

The highest-value product could be a once-daily formulation with reduced food dependence, but the development burden is greater. Such a product would need convincing comparative pharmacokinetic data and a clear prescribing advantage.

Revenue exposure is primarily linked to the menopause hormone-therapy market, where competition includes generic estradiol, generic micronized progesterone, transdermal estrogen products, and other combination therapies. Bijuva’s commercial value depends on adherence, convenience, payer coverage, and the ability to preserve a fixed-dose combination premium after generic entry.

Key Takeaways

• Bijuva is a fixed-dose oral softgel containing 1 mg estradiol and 100 mg progesterone.
• Peanut oil is the clearest excipient-related commercial vulnerability.
• Peanut-oil replacement is the most practical near-term reformulation opportunity.
• Self-emulsifying systems could reduce food-effect variability but require stronger pharmacokinetic support.
• Non-gelatin shells offer geographic and specialty-market advantages but create manufacturing and stability risks.
• Bijuva is subject to generic, not biosimilar, competition.
• The likely FDA exclusivity period associated with new clinical investigations ended around October 2021, while patent protection must be assessed separately.
• Excipient patents are strongest when linked to measurable improvements in stability, dissolution, bioavailability, or food-effect performance.
• A direct peanut-oil-free generic is likely to face fewer development barriers than a fundamentally redesigned delivery system.
• The most defensible commercial strategy combines allergen reduction, stable lipid delivery, validated softgel manufacturing, and a differentiated regulatory position.

FAQs

Can Bijuva be reformulated without peanut oil?

Yes. A sponsor could evaluate alternative lipid vehicles, but the replacement must preserve assay, stability, dissolution, bioavailability, and capsule compatibility. The change would require regulatory support.

Would a vegetarian Bijuva capsule be a new drug?

Not necessarily. The regulatory pathway would depend on whether the shell change preserves pharmaceutical performance and whether the product is developed as a generic, an NDA supplement, or a 505(b)(2) product.

Is peanut oil essential for progesterone absorption?

No. Peanut oil is one vehicle capable of supporting delivery. Other lipid systems may be suitable, but they must be evaluated for progesterone solubilization, precipitation, food effect, and bioequivalence.

Can a generic Bijuva use different inactive ingredients?

Yes, subject to the applicable FDA pathway and requirements for pharmaceutical equivalence, bioequivalence, safety, quality, and labeling. A different excipient profile may create technical advantages but also add development risk.

Does Bijuva have biosimilar competition?

No. Bijuva contains chemically synthesized estradiol and progesterone. Competitive products would proceed through generic-drug or other small-molecule FDA pathways rather than the biosimilar pathway.

References

1. U.S. Food and Drug Administration. (2018). Bijuva prescribing information. TherapeuticsMD, Inc.

2. U.S. National Library of Medicine. (n.d.). DailyMed: Bijuva estradiol and progesterone capsule.

3. U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations: Orange Book.

4. U.S. Food and Drug Administration. (n.d.). Hatch-Waxman Amendments and abbreviated new drug applications.

5. U.S. Food and Drug Administration. (2022). Applications covered by section 505(b)(2).